Medical Pharmacology Chapter 36:  Antiviral Drugs

Previous Page Page Forward
Section Table of Contents
Site Table of Contents

Previous Page

Page Forward

Section Table of Contents

Site Table of Contents


  1. Flexner C Antiretroviral Agents and Treatment of HIV Infection, Chapter 59  in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011.

  2. Fauci AS Lane HC Chapter 226, Human Immunodeficiency Virus Disease:  AIDS and Related Disorders, in Harrison's Online   (Kasper DL Fauci AS Hauser SL Longo DL Jameson JL Loscalzo J, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015 (on-line edition)

  3. Longo DL Fauci AS  188, The Human Retroviruses, in Harrison's Online   (Dan L. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies, Inc. 2012.

  4. Woster PM Chapter 43:  Antiviral Agents and Protease Inhibitors in Foye's Principles of Medicinal Chemistry 6e, Lemke, TL Williams DA, eds; Roche VG Zito SW, asst eds) Wolters Kluwer|Lippincott Williams & Wilkins 1214, 2008.

  5. HIV Overview:  The HIV Life Cycle, Education Materials, AIDSinfo, NIH

  6. Tsibris AMN Hirsch MS Chapter 130 Antiretroviral Therapy for Human Immunodeficiency Virus Infection in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8e (Bennett JE Bolin R Blaser, eds) Elsevier, Inc/Saunders 2015, online version.

  7. Safrin S Chapter 49:  Antiviral Agents:  Antiretroviral Agents in Basic & Clinical Pharmacology 13e (Katzung BG Trevor AJ, eds) 2015, online edition.

  8. Wensing AM Calvez V Gunthard JF Johnson VA Paredes R Pillay D Shafer RW Richman DD Special Contribution:  2014 Update of the Drug Resistance Multations in HIV-1 Topics in Antivral Medicine 22(3)  June/July 2014,

  9. AIDSinfo:  Guidelines for the Use of Antriretroviral Agents in HIV-1-Infected Adults and Adolescents (2015)

  10. HIV Drug Resistance Data Base (Stanford University):  Integrase Inhibitor Resistance Notes (3/2014),

  11. Min S Sloan L DeJesus E Hawkins T McCurdy L Song I Stroder R Chen S Underwood M Fujiwara T Piscitelli S Lalezari J Antiviral activity, safety, and pharmacokinetics/parhmacodynamics of dolutegravir as 10-day monotherapy in HIV-1 infected adults.  AIDS 25:  1737-1745 2011. ;,_safety,_and.7.pdf

  12. Walmsley SL Antela A Clumeck N Duiculescu D Eberhard A Gutierrez F Hocqueloux L Maggiolo F Sandkovsky US Granier C Pappa K Wynne B Min S Nichols G for the SINGLE Investigators.  Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection. N Engl J Med 369(19) 1807-1818. November 7, 2013. ;

  13. Dolutegravir

  14. Eron JJ Clotet B Durant J Katlama C Kumar P Lazzarin A Poizot-Martin I Richmond G Soriano V Ait-Khaled M Fujiwara T Huang J Min S Vavro C Yeo J for the VIKING Study Group.  Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV Type 1 infection:  24-week results of the VIKING study.  Journal of Infect. Dis. 213(3) 640-748. 2013.

  15. Katz MH Zolopa AR HIV Infection & AIDS, Chapter 31 in Current Medical Diagnosis & Treatment 2015 (Papadakis MA McPhee SJ Rabow MW, eds), 54th edition, McGraw-Hill Education, 2015.

  16. Wood BR, Medical Director, NW AETC ECHO, Assistant Professor of Medicine, University of Washington. Dolutegravir (Tivicay):  A Next Generation Integrase Inhibitor.

  17. Catellino S Moss L Wagner D Borland J Song I Chen S Lou Y Min SS Goljer I Culp A Piscitelli SC Savina PM Metabolism, exretion and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.  Antimicro Agents Chemother 57(8) 3336-3346, August 2013.

  18. Evering TH Markowitz M HIV-1 Integrase Inhibitors PRN Notebook 13 1-9, June 2008

  19. OCT2:  OCT2 Transporter (organic Cation Transport 2 / SLC22A1; Knowledge Center Solvo Biotechnology

  20. Koepsell H Endou H The SLC22 drug transporter family. Pflugers Arch, 2004. 447(5): p. 666-76.

  21. Motohashi, H Uwai Y Hiramoto K Okuda M Inui K Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol,  503(1-3): p. 25-30 2004.

  22. Jonker JW. and  Schinkel AH, Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther, 308(1): p. 2-9 2004. .

  23. Koepsell H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci,  25(7): p. 375-81 2004.

  24. StraightHealthcare Ogranic Cation Transporter 2 (OCT2)



This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.